- |||||||||| Leukine (sargramostim) / Partner Therap
Enrollment change, Trial withdrawal: Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent (clinicaltrials.gov) - Feb 17, 2016 P1, N=0, Withdrawn, Active, not recruiting --> Suspended N=20 --> 0 | Recruiting --> Withdrawn
- |||||||||| Leukine (sargramostim) / Partner Therap
Trial primary completion date: Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) - Feb 12, 2016 P2, N=40, Recruiting, N=20 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Jan 2016 --> Jun 2016
- |||||||||| Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Feb 8, 2016 P1, N=51, Active, not recruiting, Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Jan 2016 --> Jan 2017
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Enrollment closed, Trial primary completion date: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma (clinicaltrials.gov) - Jan 26, 2016 P1/2, N=40, Active, not recruiting, Trial primary completion date: Jan 2016 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> May 2018
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Trial primary completion date: Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 25, 2016 P2/3, N=60, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> May 2018 Trial primary completion date: Dec 2015 --> Jan 2017
- |||||||||| Leukine (sargramostim) / Partner Therap
Enrollment open, Trial initiation date, Trial primary completion date: GRID: GM-CSF to Decrease ICU Acquired Infections (clinicaltrials.gov) - Jan 20, 2016 P3, N=488, Recruiting, Trial primary completion date: Dec 2015 --> Jan 2017 Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Sep 2015 | Trial primary completion date: Mar 2018 --> Sep 2018
- |||||||||| Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Jan 17, 2016 P1, N=42, Active, not recruiting, Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Sep 2015 --> May 2016
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
New P2 trial: NB2013-HR German (GPOH) / Dutch (DCOG) Trial (clinicaltrials.gov) - Dec 29, 2015 P2, N=36, Recruiting,
- |||||||||| Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Trial primary completion date: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) - Nov 22, 2015 P2, N=300, Recruiting, Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- |||||||||| AE 37 / Generex, Leukine (sargramostim) / Partner Therap, GLSI-100 / Greenwich LifeSci
Trial primary completion date: BAMC-C.2007.098: Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) - Nov 17, 2015 P2, N=600, Active, not recruiting, Trial primary completion date: Dec 2014 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- |||||||||| Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma (clinicaltrials.gov) - Nov 5, 2015 P2, N=42, Completed, Trial primary completion date: Dec 2016 --> Dec 2025 Trial primary completion date: Sep 2013 --> Dec 2006
- |||||||||| Leukine (sargramostim) / Partner Therap
Trial completion, Trial primary completion date: Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness? (clinicaltrials.gov) - Oct 6, 2015 P1/2, N=70, Completed, Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Jan 2015
- |||||||||| Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Enrollment change, Trial initiation date, Trial withdrawal: Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (clinicaltrials.gov) - Oct 5, 2015 P2, N=0, Withdrawn, Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Jan 2015 N=54 --> 0 | Initiation date: Mar 2015 --> Jun 2015 | Not yet recruiting --> Withdrawn
|